Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DHFR | P00374 | 1/20 | 0.36 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.33 |
| ▸ | EPAS1 | Q99814 | 1/20 | 0.33 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.32 |
| ▸ | MAOB | P27338 | 3/20 | 0.32 |
| ▸ | PPARD | Q03181 | 1/20 | 0.32 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.32 |
| ▸ | ACP1 | P24666 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.30 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.30 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5863302 | 0.82 | LTA4H (0.47) | — | |
| SCHEMBL5863815 | 0.82 | HIF1A (0.45) | DHFRHIF1AEPAS1MEN1KMT2A | |
| SCHEMBL5863905 | 0.80 | DHFR (0.48) | DHFRHIF1AEPAS1MEN1KMT2A | |
| SCHEMBL674989 | 0.75 | TNK2 (0.40) | DHFRHSD11B1ACP1MEN1KMT2A | |
| SCHEMBL15100422 | 0.71 | HSD11B1 (0.40) | DHFRHSD11B1MEN1KMT2AKDM4C | |
| SCHEMBL15100425 | 0.71 | HSD11B1 (0.40) | DHFRHSD11B1MEN1KMT2AKDM4C | |
| SCHEMBL5535487 | 0.71 | HSD11B1 (0.40) | DHFRHSD11B1MEN1KMT2AKDM4C | |
| SCHEMBL7172082 | 0.71 | HSD11B1 (0.40) | DHFRHSD11B1MEN1KMT2AKDM4C | |
| SCHEMBL5863517 | 0.70 | TP53 (0.31) | DHFR | |
| SCHEMBL5863688 | 0.70 | RAB9A (0.52) | HIF1AMEN1KMT2ANPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7053212-B2 | Acyclic amide and sulfonamide ligands for the estrogen receptor | PFIZER INC. (US) | 2006-05-30 | — | — | US | disclosed |
| EP-1542967-A1 | AMIDE AND SULFONAMIDE LIGANDS FOR THE ESTROGEN RECEPTOR | Pfizer Products Inc. (US) | 2005-06-22 | — | — | EP | disclosed |
| US-20040110767-A1 | Acyclic amide and sulfonamide ligands for the estrogen receptor | PFIZER INC | 2004-06-10 | — | — | US | disclosed |
| WO-2004026823-A1 | AMIDE AND SULFONAMIDE LIGANDS FOR THE ESTROGEN RECEPTOR | PFIZER PRODUCTS INC. (US) | 2004-04-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040110767-A1 | Acyclic amide and sulfonamide ligands for the estrogen receptor | GHSR, GPER1, SSTR1 | DHFR 3070/4885HIF1A 1261/4885EPAS1 1970/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.